Bayer's 35% Surge Meets a Technical Ceiling Ahead of Pivotal August Court Dates

Bayer shares have surged 94.5% from their 52-week low after a landmark Supreme Court ruling, but the rally is stalling with technical overextension and two critical court dates ahead.

Bayer shares have nearly doubled from their 52-week trough, but the blistering rally is showing signs of exhaustion. After vaulting almost 35% in a single month on the back of a landmark Supreme Court victory, the stock slipped 1.67% on Tuesday to €48.81, a move that looks minor in isolation but marks the first real pullback in a weeks-long ascent. For investors already nursing gains of 28% year-to-date, the question is whether this is a mere breather or the start of a deeper correction as two court dates loom.

The momentum began with the US Supreme Court’s 7–2 ruling on June 25 in the case of Monsanto v. Durnell. The justices held that plaintiffs can no longer argue that Roundup’s warning label inadequately addressed cancer risks — a decision that triggered Bayer’s biggest single-day gain in 23 years. The stock has added another 35% since, lifting the market capitalisation to roughly €49.2 billion. Bargain hunters who bought at the 52-week low of €25.09 a year ago are sitting on a 94.5% paper profit.

Bayer is now leveraging the ruling on multiple fronts. In San Francisco, a federal judge heard arguments on the company’s motion to dismiss a bundled proceeding covering roughly 4,000 lawsuits. The judge called both sides’ answers “unsatisfactory” and left the outcome open. Separately, a Missouri state court will convene on August 19 to decide whether to grant final approval to the class-action settlement Bayer has proposed for the remaining glyphosate claims. If the judge signs off, a major overhang is removed; if not, the market will have to reassess the risk premium baked into the stock.

Analysts have responded to the legal shift by raising their sights. Barclays lifted its price target from €50 to €60 on July 14, citing lower litigation risk and a brighter outlook for the crop-science division. JPMorgan maintains an “Overweight” call with a €50 target, while UBS rates the stock a “Buy” at €52 and Jefferies remains on “Hold”. The upgrades reflect a broader reassessment of Bayer’s risk-reward profile, which is increasingly influenced by operational momentum rather than legal uncertainty. An additional pillar came via a €3 billion capital infusion from Apollo, strengthening the balance sheet.

Yet the technical picture looks stretched. The relative-strength index sits at 63.2 — not yet in overbought territory but well above the mid-point. The stock trades 20% above its 50-day moving average of €40.64 and nearly 29% above its 200-day line of €37.90, distances that historically invite profit-taking. Annualised 30-day volatility has climbed to 61.35%, underscoring the nervousness beneath the surface. The current price is just 9.4% below the 52-week high of €53.86 hit on July 3, leaving limited upside if the legal catalysts do not materialise.

The bull case rests on a clean sweep. Bayer argues the Supreme Court decision compels dismissal of the federal proceeding, and approval of the Missouri settlement would erase one of the last big liability question marks. Operationally, JPMorgan analyst Richard Vosser expects solid second-quarter results in early August, supported by unchanged full-year guidance. Regulatory tailwinds also help: Dicamba was recertified for two more growing seasons, and the EPA has signalled no ban for the herbicide atrazine.

Sceptics caution that the Supreme Court ruling is narrow. It addresses only the failure-to-warn claim, leaving other causes of action — such as design defect and negligence — untouched. The federal hearing in San Francisco ended without a clear win for Bayer, and plaintiff lawyers have vowed to keep the multidistrict litigation alive. More ominously, Bayer has provisioned roughly €5 billion for litigation expenses in 2026, the bulk of it for glyphosate settlements, regardless of how the Missouri hearing goes. Over 60,000 state-court cases remain unaffected by the current proceedings.

The next weeks will be decisive. The first test arrives in early August with the quarterly report, where investors will scrutinise cash flow and debt reduction progress. The Missouri settlement hearing later that month will determine whether the legal cleanup accelerates or stalls. For now, the market’s optimism has driven the stock to levels that leave little room for disappointment — and with volatility running high, the path from here depends entirely on which way the judge in Missouri rules.